Today's focus
1. Xiansheng Pharmaceutical: Net profit is expected to increase 34 to 35 times year-on-year in the first half of the year
$SIMCERE PHARMA (02096.HK)$It was announced that revenue for the first half of 2023 is expected to reach about RMB 3.349 billion to RMB 3.409 billion, up about 24.0% to 26.3% year on year; profit attributable to the company's equity shareholders is expected to be around RMB 2,245 billion to RMB 2,305 billion, up 3407.81% to 3501.56% year on year.
2. Zhou Heiya announced Yingxi: Expected net profit of 90 million yuan to 110 million yuan in the first half of the year
$ZHOU HEI YA (01458.HK)$According to the announcement, the Group expects net profit for the first half of the year to be between RMB 90 million and RMB 11 million, while net profit for the same period in 2022 is RMB 18.4 million; total revenue for the reporting period will be between RMB 1,400 million and RMB 1,420 million, while total revenue for the same period in 2022 will be RMB 1,181.1 billion.
3. Evergrande Motor: Reached all guidelines for the resumption of trading and plans to resume trading on July 28
$EVERG VEHICLE (00708.HK)$It was announced that trading of the company's shares will be suspended from 9:00 a.m. on April 1, 2022. Since the company has reached all guidelines for the resumption of trading, the company has applied to the Stock Exchange to resume trading of the company's shares on the Stock Exchange starting at 9:00 a.m. on July 28, 2023 (Friday).
4. Ganfeng Lithium plans to acquire 70% of Mengjin Mining's shares for 1.42 billion yuan
$GANFENGLITHIUM (01772.HK)$It was announced that on July 27, 2023, the buyer, Jiangxi Ganfeng Lithium Group Co., Ltd., the seller (company chairman and executive director Li Liangbin), Xu, and the target company entered into an equity transfer agreement. Based on this, the buyer agreed to acquire 70% of the shares of the target company, Jaohuangqi Mengjin Mining Development Co., Ltd., from the seller at a total cost of RMB 1.42 billion.
Financial data
Prada (01913) had net medium-term earnings of €2,232 billion, up 20.5% year over year (at a fixed exchange rate)
Auto Home-S (02518)'s second-quarter results continued to improve, total revenue increased 6% year on year, and the average number of daily mobile users rose sharply by 31.7% year on year
Zhou Heiya (01458) released Yingxi: It is estimated that the net profit for the first half of the year is 90 million yuan - 110 million yuan, and the offline store business will gradually resume
DaliPu Holdings (01921) Yingxi: Expected medium-term net profit of not less than 53 million yuan, an increase of more than 70% over the previous year
Xiansheng Pharmaceutical (02096) is Yingxi, which expects shareholders to account for profit of about 2,245 billion yuan to 2.305 billion yuan in the first half of the year, an increase of 3407.81% to 3501.56% over the previous year
Taking multiple measures to promote the gradual recovery of its main business Chinese Medicine (00570) expects net profit in the first half of the year to increase 45%-55% year-on-year
China Aluminum Can (06898) Yingxi: Net profit is expected to increase by no less than 30% year-on-year in the first half of the year
Operational data
China Railway (00390) signed new contracts totaling 606.37 billion yuan in April-June
Xintian Green Energy (00956) completed 3.71 million megawatt-hours of power generation in the second quarter, an increase of 0.21% over the previous year
Resumption of trading
Evergrande Motor (00708): Reached all guidelines to resume trading to resume trading on July 28
Investment and operation
China Tongmei (01763): CNNC High Energy and Anhui Yingshang Chengdong Hospital sign a cooperation agreement for cancer radiotherapy center
Beijing Holdings (00392): It is expected that the dividend per share in 2023 will not be less than 30% of the recurring earnings per share
Ganfeng Lithium (01772) plans to acquire 70% of Mengjin Mining's shares for 1.42 billion yuan
Cansino Biotech (06185): CS-2047 tetanus vaccine approved for clinical trials
Xiansheng Pharmaceutical (02096): SIM0278 injection (IL-2 mutated Fc fusion protein) received a drug clinical trial approval notice issued by the China Drug Administration and is intended for use in moderate to severe atopic dermatitis
China Biopharmaceutical (01177) “injectable trastuzumab” approved for marketing
Repurchase cancellation
Dongfeng Group Co., Ltd. (00489) spent HK$9.342 million to buy back 2.53 million shares on July 27
Mengniu Dairy (02319) spent HK$2,961 million to buy back 105,000 shares on July 27
Jinke Services (09666) spent HK$8.6599 million to buy back 700,000 shares on July 27
Tianli International Holdings (01773) spent HK$5.3354 million to buy back 2 million shares on July 27
Editor/Somer